Skip to content

Taxanes—including paclitaxel, docetaxel, and cabazitaxel—constitute a class of cytotoxic chemotherapeutic agents that target microtubules and are widely used in the treatment of most solid tumors: gastric, prostate, head and neck, pancreatic, non-small cell lung, ovarian, and breast cancers. Their efficacy, however, is hampered by a major obstacle: chemoresistance, the leading cause of therapeutic failure. The scale of the problem is considerable, as nearly 80% of breast tumors are resistant to chemotherapy and, among high-grade serous ovarian cancers—initially chemosensitive in 48% to 86% of cases—a large majority develop secondary resistance. This review takes stock of the mechanisms of resistance and of the emerging strategies to overcome it, with a focus on breast and ovarian cancers.

The authors first recall that the mechanism of action of paclitaxel is better understood than it once was. As a tubulin-binding agent, it promotes microtubule assembly and protects them from depolymerization. Long regarded as a "mitotic poison" arresting cells in M phase at high concentrations (0.25 to 1 μM), it in fact acts, at clinically relevant intratumoral concentrations (on the order of 5 to 50 nM), without substantially altering polymer mass or inducing marked mitotic arrest. At these doses, it prolongs the duration of mitosis and induces multipolar divisions leading to aneuploidy. This revised understanding of the mechanism sheds light on resistance.

The body of work catalogs several families of resistance mechanisms: dysregulation of mitotic functions, metabolic reprogramming, and also non-cell-autonomous mechanisms involving the crosstalk between the tumor and its microenvironment. This diversity—and in particular the discovery of these tumor–microenvironment exchanges and of metabolic plasticity—paves the way for personalized medicine. From this perspective, the identification of predictive biomarkers becomes crucial for selecting patients likely to benefit from taxane-based chemotherapy and for avoiding ineffective treatment, with its attendant adverse effects, in those presenting innate resistance. Among the biomarkers currently under evaluation are microtubule-associated proteins, tumor-infiltrating lymphocytes, and predictive signatures, whose accuracy could be improved by machine learning approaches.

Finally, the authors review the emerging strategies for circumventing chemoresistance: taxane analogues, novel formulations, dual-action inhibitors, and drug combinations. By bringing together a better understanding of paclitaxel's effect on microtubule dynamics, the characterization of resistance mechanisms, and the development of predictive biomarkers, this synthesis outlines the contours of a more individualized management of taxane-treated cancers.